231 related articles for article (PubMed ID: 35431929)
1. How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.
Robinson BWS; Redwood AJ; Creaney J
Front Pharmacol; 2022; 13():858557. PubMed ID: 35431929
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
Nowak AK; Chin WL; Keam S; Cook A
Lung Cancer; 2021 Dec; 162():162-168. PubMed ID: 34823106
[TBL] [Abstract][Full Text] [Related]
4. Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.
Kuryk L; Rodella G; Staniszewska M; Pancer KW; Wieczorek M; Salmaso S; Caliceti P; Garofalo M
Front Oncol; 2022; 12():916839. PubMed ID: 35785199
[TBL] [Abstract][Full Text] [Related]
5. Authors' response: Mezei et al's "Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis".
Marinaccio A; Consonni D; Mensi C; Mirabelli D; Migliore E; Magnani C; Di Marzio D; Gennaro V; Mazzoleni G; Girardi P; Negro C; Romanelli A; Chellini E; Grappasonni I; Madeo G; Romeo E; Ascoli V; Carrozza F; Angelillo IF; Cavone D; Tumino R; Melis M; Curti S; Brandi G; Mattioli S; Iavicoli S;
Scand J Work Environ Health; 2021 Jan; 47(1):87-89. PubMed ID: 33388783
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy advances for mesothelioma treatment.
Bakker E; Guazzelli A; Ashtiani F; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Rev Anticancer Ther; 2017 Sep; 17(9):799-814. PubMed ID: 28724330
[TBL] [Abstract][Full Text] [Related]
7. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.
Robinson C; Dick IM; Wise MJ; Holloway A; Diyagama D; Robinson BW; Creaney J; Lake RA
BMC Cancer; 2015 Dec; 15():983. PubMed ID: 26680231
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.
Nabavi N; Wei J; Lin D; Collins CC; Gout PW; Wang Y
Front Genet; 2018; 9():232. PubMed ID: 30022998
[TBL] [Abstract][Full Text] [Related]
9. Update of potency factors for asbestos-related lung cancer and mesothelioma.
Berman DW; Crump KS
Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
[TBL] [Abstract][Full Text] [Related]
10. Consensus Report of the 2015 Weinman International Conference on Mesothelioma.
Carbone M; Kanodia S; Chao A; Miller A; Wali A; Weissman D; Adjei A; Baumann F; Boffetta P; Buck B; de Perrot M; Dogan AU; Gavett S; Gualtieri A; Hassan R; Hesdorffer M; Hirsch FR; Larson D; Mao W; Masten S; Pass HI; Peto J; Pira E; Steele I; Tsao A; Woodard GA; Yang H; Malik S
J Thorac Oncol; 2016 Aug; 11(8):1246-1262. PubMed ID: 27453164
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies in malignant pleural mesothelioma.
Cinausero M; Rihawi K; Cortiula F; Follador A; Fasola G; Ardizzoni A
Crit Rev Oncol Hematol; 2019 Dec; 144():102815. PubMed ID: 31670225
[TBL] [Abstract][Full Text] [Related]
12. Novel and Future Treatment Options in Mesothelioma: A Systematic Review.
Štrbac D; Dolžan V
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216091
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
Gray SG; Mutti L
Transl Lung Cancer Res; 2020 Feb; 9(Suppl 1):S100-S119. PubMed ID: 32206576
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy-based treatment strategies for malignant mesothelioma.
Schwarzenberger P; Byrne P; Kolls JK
Curr Opin Mol Ther; 1999 Feb; 1(1):104-11. PubMed ID: 11249674
[TBL] [Abstract][Full Text] [Related]
15. Advances in treatment of mesothelioma.
Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
[TBL] [Abstract][Full Text] [Related]
16. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Carbone M; Adusumilli PS; Alexander HR; Baas P; Bardelli F; Bononi A; Bueno R; Felley-Bosco E; Galateau-Salle F; Jablons D; Mansfield AS; Minaai M; de Perrot M; Pesavento P; Rusch V; Severson DT; Taioli E; Tsao A; Woodard G; Yang H; Zauderer MG; Pass HI
CA Cancer J Clin; 2019 Sep; 69(5):402-429. PubMed ID: 31283845
[TBL] [Abstract][Full Text] [Related]
17. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
19. Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis.
Mezei G; Chang ET; Mowat FS; Moolgavkar SH
Scand J Work Environ Health; 2021 Jan; 47(1):85-86. PubMed ID: 32626907
[TBL] [Abstract][Full Text] [Related]
20. Advances in systemic therapy for malignant mesothelioma: future perspectives.
Sobhani N; Corona SP; Bonazza D; Ianza A; Pivetta T; Roviello G; Cortale M; Guglielmi A; Zanconati F; Generali D
Future Oncol; 2017 Oct; 13(23):2083-2101. PubMed ID: 28984470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
